CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Travere Therapeutics and Vifor Pharma Establish Licensing Agreement for Commercialization

Life Sciences Review Life Sciences Review | Thursday, September 30, 2021
Tweet

Sparsentan has been granted exclusive marketing rights in Europe, Australia, and New Zealand by Vifor Pharma.


FREMONT, CA: Travere Therapeutics, Inc. and Vifor Pharma have formed a joint venture and licensing agreement to develop and commercialize sparsentan in Europe, Australia, and New Zealand. Sparsentan is a novel investigational product candidate undergoing crucial Phase 3 clinical trials to treat FSGS and IgAN. These two rare progressive kidney diseases are significant causes of end-stage kidney disease. At the moment, there are no licensed medications for FSGS or IgAN. Sparsentan has been given Orphan Drug Designation in the United States and Europe to treat FSGS and IgAN.


“Our goal is for sparsentan to become the new global treatment standard for people living with FSGS and IgAN; this collaboration marks an important step forward in this journey,” says Eric Dube, Ph.D., Chief Executive Officer of Travere Therapeutics. “Vifor Pharma is a global leader in nephrology with established commercialization expertise in Europe, Australia and New Zealand and this agreement aligns our two companies with the common goal of maximizing the number of people who can access sparsentan, if approved in these regions. In addition, this collaboration will further strengthen our financial foundation and allow our organization to focus on planned future launches of sparsentan in the U.S.”


Vifor Pharma will get exclusive commercialization rights for sparsentan throughout Europe, Australia, and New Zealand under the agreement terms. Travere will receive a $55 million upfront payment and be entitled to additional payments of up to $135 million based on completing particular regulatory and market access objectives. 


Vifor Pharma will also make other payments in the form of sales milestones and tiered double-digit royalties on sparsentan's net sales in Europe, Australia, and New Zealand, with the maximum royalty rate being 40 percent.


“This agreement highlights that Vifor Pharma has become a company of choice for organizations committed to partnering innovative nephrology assets,” Abbas Hussain, chief executive officer of Vifor Pharma Group, comments. “With sparsentan, we will further expand our growing nephrology pipeline into FSGS and IgAN. There are currently no effective or approved therapies for these two rare kidney disorders, resulting in a significant unmet medical need among these patient populations. We look forward to working closely with Travere, who is responsible for the ongoing clinical development program of sparsentan, and to leveraging our commercial expertise to bring this highly promising, innovative treatment option to more than 150,000 patients living with FSGS and IgAN in the licensed territories as soon as possible.”


Following the recently disclosed good topline interim findings from the current pivotal Phase 3 PROTECT Study of sparsentan in IgAN, Travere and Vifor Pharma will assess sparsentan's regulatory approach in Europe including the possibility of filing a joint marketing authorization application for both FSGS and IgAN in 2022. Eventually, Vifor Pharma will assume responsibility for and control of marketing authorizations in the licensed areas. Vifor Pharma will be responsible for all commercialization activities in the licensed regions if sparsentan is authorized. Travere will continue to be accountable for sparsentan's clinical development and retain all rights to sparsentan in the United States and the rest of the globe. Travere is still liable to pay Ligand Pharmaceuticals upon the achievement of certain regulatory and commercial milestones, as well as an annual royalty of between 15 percent and 17 percent of global net product sales.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Antibodies: Immunoglobulin Isotypes

Life Science Consulting Services Trends

Rani Therapeutics and Celltrion Partner to Develop Oral Monoclonal Antibodies

ProPhase Labs Acquires BE-Smart Esophageal Pre-Cancer Screening Test

The Influence of Pharmaceutical Distributors on U.S. Drug Expenditures

Tips to Improve Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/travere-therapeutics-and-vifor-pharma-establish-licensing-agreement-for-commercialization-nwid-579.html